Effect of recombinant human erythropoietin in preterm infants

Απλή σελίδα τεκμηρίου
dc.contributor.authorKrallis, N.en
dc.contributor.authorCholevas, V.en
dc.contributor.authorMavridis, A.en
dc.contributor.authorGeorgiou, I.en
dc.contributor.authorBourantas, K.en
dc.contributor.authorAndronikou, S.en
dc.date.accessioned2015-11-24T19:22:35Z
dc.date.available2015-11-24T19:22:35Z
dc.identifier.issn0902-4441-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22174
dc.rightsDefault Licence-
dc.subject2,3-Diphosphoglycerate/blooden
dc.subjectAdenosine Triphosphate/blooden
dc.subjectAnemia/drug therapy/*prevention & controlen
dc.subjectEnergy Metabolismen
dc.subjectErythrocytes/*metabolismen
dc.subjectErythropoietin/blood/*therapeutic useen
dc.subjectFollow-Up Studiesen
dc.subjectGestational Ageen
dc.subjectHumansen
dc.subjectInfant, Newbornen
dc.subject*Infant, Prematureen
dc.subjectPhosphates/*blooden
dc.subjectProspective Studiesen
dc.subjectReceptors, Transferrin/blooden
dc.subjectRecombinant Proteinsen
dc.subjectTreatment Outcomeen
dc.titleEffect of recombinant human erythropoietin in preterm infantsen
heal.abstractTwenty-five premature infants (mean gestational age+/-SD, 31.4+/-1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature infants with a mean gestational age of 32.2+/-2.3 weeks who did not receive rHuEpo. Haematological indices, haemoglobin and serum phosphate (Pi), and red blood cell (RBC) phosphate metabolites (ATP, 2,3-DPG, RBCPi) were tested monthly until the 6th month and thereafter at the 9th and 12th months of life. The level of serum soluble transferrin receptors (sTfR) correlated significantly with rHuEpo (p<0.05). The ratio of sTfR to log (ferritin) was significantly higher (p<0.001) in the infants treated with rHuEpo than the controls. Intracellular organic and inorganic Pi changes were not affected by the Epo administration. The RBC 2,3-DPG seemed adequate in infants receiving rHuEpo.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10480285-
heal.journalNameEur J Haematolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ